Table 1 Correlation between GNA13 expression and clinical and pathological characters in HCC patients.

From: High expression of GNA13 is associated with poor prognosis in hepatocellular carcinoma

Variable

All cases N = 246 (%)

Low GNA13 expression N = 98 (%)

High GNA13 expression N = 148 (%)

χ2

P value

Age (years)a

   

0.329

0.566

 ≤49

121 (49.2)

46 (38.0)

75 (62.0)

  

 >49

125 (50.8)

52 (41.6)

73 (58.4)

  

Mean ± SD (49.4 ± 12.1)

Gender

   

1.216

0.270

 Female

21 (8.5)

6 (28.6)

15 (71.4)

  

 Male

225 (91.5)

92 (40.9)

133 (59.1)

  

HBsAg

   

0.665

0.415

 Yes

216 (87.8)

84 (38.9)

132 (61.1)

  

 No

30 (12.2)

14 (46.7)

16 (53.3)

  

AFP (ng/ml)

   

1.981

0.159

 <200

112 (45.5)

50 (44.6)

62 (55.4)

  

 ≥200

134 (54.5)

48 (35.8)

86 (64.2)

  

Liver cirrhosis

   

3.413

0.065

 Yes

191 (77.6)

82 (42.9)

109 (57.1)

  

 No

55 (22.4)

16 (29.1)

39 (70.9)

  

Tumor size (cm)

   

0.923

0.337

 ≤5

89 (36.2)

39 (43.8)

50 (56.2)

  

 >5

157 (63.8)

59 (37.6)

98 (62.4)

  

Tumor multiplicity

   

8.400

0.004*

 Single

202 (82.1)

89 (44.1)

113 (55.9)

  

 Multiple

44 (17.9)

9 (20.5)

35 (79.5)

  

Pathological grade

   

2.705

0.439

 Well (I)

20 (8.1)

11 (55.0)

9 (45.0)

  

 Moderate (II)

107 (43.5)

44 (41.1)

63 (58.9)

  

 Poor (III)

114 (46.4)

41 (36.0)

73 (64.0)

  

 Undifferentiated (IV)

5 (2.0)

2 (40.0)

3 (60.0)

  

TNM stage

   

14.644

0.002*

 I

160 (65.0)

77 (48.1)

83 (51.9)

  

 II

18 (7.3)

6 (33.3)

12 (66.7)

  

 III

56 (22.8)

11 (19.6)

45 (80.4)

  

 IV

12 (4.9)

4 (33.3)

8 (66.7)

  

BCLC stage

   

11.295

0.010*

 0

9 (3.7)

6 (66.7)

3 (33.3)

  

 A

171 (69.5)

76 (44.4)

95 (55.6)

  

 B

38 (15.4)

8 (21.1)

30 (78.9)

  

 C

28 (11.4)

8 (28.6)

20 (71.4)

  

Vascular invasion

   

2.514

0.113

 Yes

18 (7.3)

4 (22.2)

14 (77.8)

  

 No

228 (92.7)

94 (41.2)

134 (58.8)

  
  1. apatients were divided according to the median age; AFP: alpha-fetoprotein; HBsAg: hepatitis B surface antigen.
  2. *P < 0.05.